| Cash Flow | 2026-06-30 |
|---|---|
| Purchase of property and equipment | 0 |
| Convertible notes receivable advances | 0 |
| Net cash used in investing activities | 0 |
| Change in reserve for supplier advances for purchases | 0 |
| Amortization of convertible notes receivable discount | 0 |
| Amortization of operating lease right-of-use assets | 0 |
| Increase in other receivable | 0 |
| Increase in due to a related party | 0 |
| Decrease in operating lease obligations | 0 |
| Net (loss) income | -4,408,447 |
| Net gain on settlement of debt and accrued expenses | 140,500 |
| Stock-based compensation | 14,833 |
| Change in fair value of convertible notes and derivatives | -3,526,007 |
| Amortization of loan discount | 132,175 |
| Increase in accounts receivable | 394 |
| Decrease (increase) in accounts receivable - related party, net | -2,818 |
| Decrease in inventory | -3,952 |
| Increase in prepaid expenses and other current assets | 16,000 |
| (decrease) increase in accounts payable | 36,043 |
| Increase in accrued expenses | 127,853 |
| Increase in accrued payroll due to officers | 135,048 |
| Increase (decrease) in accrued interest to related parties | 12,250 |
| Depreciation | 4,859 |
| Increase in due from employee - related party, net | 9,511 |
| Net cash used in operating activities | -579,014 |
| Advances from related parties | 254,057 |
| Repayments to related parties | 73,000 |
| Proceeds from convertible notes | 463,001 |
| Repayment of convertible notes | 37,825 |
| Advances from notes payable | 83,250 |
| Repayments of notes payable | 122,650 |
| Net cash provided by financing activities | 566,833 |
| Net change in cash | -12,181 |
| Cash - end of period | 0 |
NUTRA PHARMA CORP (NPHC)
NUTRA PHARMA CORP (NPHC)